Virology

New data supports the utility of telomerase activation for HIV/AIDS therapy

Published in Vaccine Weekly, December 22nd, 2004

Geron Corp. (GERN) announced the publication of a research study expanding upon the use of telomerase activation to increase the lifespan and augment the antiviral activities of HIV-1-specific immune cells.

The data support the development of Geron's small-molecule telomerase activators for the treatment of patients infected with HIV-1.

The new data was published in the November 15, 2004 issue of the Journal of Immunology and authored by Dr. Rita Effros and colleagues at the department of pathology & laboratory medicine and the University of California, Los Angeles AIDS Institute, David Geffen School of Medicine, Los Angeles,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry